Understanding Kenyan policymakers' perspectives about the introduction of new maternal vaccines.

IF 2.9 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Health policy and planning Pub Date : 2024-07-02 DOI:10.1093/heapol/czae059
Rupali J Limaye, Berhaun Fesshaye, Prachi Singh, Rose Jalang'o, Rosemary Njura Njogu, Emily Miller, Jessica Schue, Molly Sauer, Clarice Lee, Ruth A Karron
{"title":"Understanding Kenyan policymakers' perspectives about the introduction of new maternal vaccines.","authors":"Rupali J Limaye, Berhaun Fesshaye, Prachi Singh, Rose Jalang'o, Rosemary Njura Njogu, Emily Miller, Jessica Schue, Molly Sauer, Clarice Lee, Ruth A Karron","doi":"10.1093/heapol/czae059","DOIUrl":null,"url":null,"abstract":"<p><p>New vaccine policy adoption is a complex process, especially in low-and-middle-income countries (LMICs), requiring country policymakers to navigate challenges such as competing priorities, human and financial resource constraints, and limited logistical capacity. Since the Expanded Programme on Immunization's (EPI) beginning, most new vaccine introductions under this structure have not been aimed at adult populations. The majority of adult vaccines offered under the EPI are not typically tested among and tailored for pregnant persons, except those that are specifically recommended for pregnancy. Given that new maternal vaccines, including RSV and GBS vaccines, are on the horizon, it is important to understand what barriers may arise during the policy development and vaccine introduction process. In this study, we sought to understand information needs among maternal immunization policymakers and decision-makers in Kenya for new vaccine maternal policy adoption through in-depth interviews with 20 participants in Nakuru and Mombasa counties in Kenya. Results were mapped to an adapted version of an established framework by Levine et al., (2010) focused on new vaccine introduction in LMICs. Participants reported that the policy process for new maternal vaccine introduction requires substantial evidence as well as coordination among diverse stakeholders. Importantly, our findings suggest that the process for new maternal vaccines does not end with the adoption of a new policy, as intended recipients and various actors can determine the success of a vaccine program. Previous shortcomings, in Kenya, and globally during HPV vaccine introduction show the need to allocate adequate resources in education of communities given the sensitive target group. With maternal vaccines targeting a sensitive group - pregnant persons- in the pipeline, we are at an opportune time to understand how to ensure successful vaccine introduction with optimal acceptance and uptake, while also addressing vaccine hesitancy to increase population benefit.</p>","PeriodicalId":12926,"journal":{"name":"Health policy and planning","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health policy and planning","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/heapol/czae059","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

New vaccine policy adoption is a complex process, especially in low-and-middle-income countries (LMICs), requiring country policymakers to navigate challenges such as competing priorities, human and financial resource constraints, and limited logistical capacity. Since the Expanded Programme on Immunization's (EPI) beginning, most new vaccine introductions under this structure have not been aimed at adult populations. The majority of adult vaccines offered under the EPI are not typically tested among and tailored for pregnant persons, except those that are specifically recommended for pregnancy. Given that new maternal vaccines, including RSV and GBS vaccines, are on the horizon, it is important to understand what barriers may arise during the policy development and vaccine introduction process. In this study, we sought to understand information needs among maternal immunization policymakers and decision-makers in Kenya for new vaccine maternal policy adoption through in-depth interviews with 20 participants in Nakuru and Mombasa counties in Kenya. Results were mapped to an adapted version of an established framework by Levine et al., (2010) focused on new vaccine introduction in LMICs. Participants reported that the policy process for new maternal vaccine introduction requires substantial evidence as well as coordination among diverse stakeholders. Importantly, our findings suggest that the process for new maternal vaccines does not end with the adoption of a new policy, as intended recipients and various actors can determine the success of a vaccine program. Previous shortcomings, in Kenya, and globally during HPV vaccine introduction show the need to allocate adequate resources in education of communities given the sensitive target group. With maternal vaccines targeting a sensitive group - pregnant persons- in the pipeline, we are at an opportune time to understand how to ensure successful vaccine introduction with optimal acceptance and uptake, while also addressing vaccine hesitancy to increase population benefit.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
了解肯尼亚决策者对引入新孕产妇疫苗的看法。
新疫苗政策的采用是一个复杂的过程,尤其是在中低收入国家(LMICs),需要国家决策者应对各种挑战,如相互竞争的优先事项、人力和财力资源的限制以及有限的后勤能力。自扩大免疫接种计划(EPI)启动以来,在这一结构下引入的大多数新疫苗并不针对成年人群。在扩大免疫规划下提供的大多数成人疫苗通常都没有在孕妇中进行测试,也没有为孕妇量身定做,除非是那些特别推荐用于孕妇的疫苗。鉴于包括 RSV 和 GBS 疫苗在内的新型孕产妇疫苗即将问世,了解政策制定和疫苗引进过程中可能出现的障碍就显得尤为重要。在本研究中,我们通过对肯尼亚纳库鲁县和蒙巴萨县的 20 名参与者进行深入访谈,试图了解肯尼亚孕产妇免疫政策制定者和决策者在采用新疫苗孕产妇政策方面的信息需求。访谈结果与 Levine 等人(2010 年)针对低收入国家引进新疫苗的既定框架的改编版进行了比对。参与者报告称,引入新的孕产妇疫苗的政策过程需要大量证据以及不同利益相关者之间的协调。重要的是,我们的研究结果表明,新孕产妇疫苗的引进过程并不会随着新政策的通过而结束,因为预期接种者和不同的参与者可以决定疫苗计划的成败。肯尼亚和全球在引入人类乳头瘤病毒(HPV)疫苗过程中存在的不足表明,鉴于目标群体的敏感性,有必要为社区教育分配充足的资源。随着针对敏感群体--孕妇--的孕产妇疫苗正在酝酿中,我们正处于了解如何确保成功引入疫苗并获得最佳接受度和吸收率的有利时机,同时还要解决疫苗犹豫不决的问题,以增加人口受益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Health policy and planning
Health policy and planning 医学-卫生保健
CiteScore
6.00
自引率
3.10%
发文量
98
审稿时长
6 months
期刊介绍: Health Policy and Planning publishes health policy and systems research focusing on low- and middle-income countries. Our journal provides an international forum for publishing original and high-quality research that addresses questions pertinent to policy-makers, public health researchers and practitioners. Health Policy and Planning is published 10 times a year.
期刊最新文献
Conceptualising maternal mental health in rural Ghana: A realist qualitative analysis. Learning Analysis of Health System Resilience. Managing medicines in decentralisation: discrepancies between national policies and local practices in primary healthcare settings in Indonesia. What is the relationship between hospital management practices and quality of care? A systematic review of the global evidence. Development partner influence on domestic health financing contributions in Senegal: a mixed methods case study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1